Medicus Pharma Ltd. (MDCX)
NASDAQ: MDCX · Real-Time Price · USD
2.040
+0.080 (4.08%)
At close: Aug 20, 2025, 4:00 PM
2.100
+0.060 (2.94%)
Pre-market: Aug 21, 2025, 4:24 AM EDT
Medicus Pharma Stock Forecast
Stock Price Forecast
The 2 analysts that cover Medicus Pharma stock have a consensus rating of "Strong Buy" and an average price target of $23.5, which forecasts a 1,051.96% increase in the stock price over the next year. The lowest target is $20 and the highest is $27.
Price Target: $23.5 (+1,051.96%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Medicus Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +1,223.53% | Aug 13, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +1,223.53% | Jul 9, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +1,223.53% | Jul 1, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +1,223.53% | Jun 23, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +1,223.53% | Jun 9, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | -2.58 | -0.96 | -0.81 | ||
| Avg | -2.51 | -1.22 | -1.14 | ||
| Low | -2.41 | -1.34 | -1.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.